Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 2/20 | 0.52 |
| ▸ | RAF1 | P04049 | 14/20 | 0.48 |
| ▸ | BRAF | P15056 | 14/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | BCR | P11274 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412491 | 0.94 | TEK (0.57) | TEKRAF1BRAFMEN1KMT2A | |
| SCHEMBL14473151 | 0.93 | TEK (0.52) | TEKRAF1BRAFMEN1KMT2A | |
| SCHEMBL4410250 | 0.93 | TEK (0.51) | TEKRAF1BRAFMEN1KMT2A | |
| SCHEMBL4565686 | 0.87 | RAF1 (0.51) | TEKRAF1BRAF | |
| SCHEMBL4413471 | 0.84 | RAF1 (0.58) | TEKRAF1BRAF | |
| SCHEMBL4420790 | 0.84 | MEN1 (0.55) | TEKRAF1BRAFMEN1KMT2A | |
| SCHEMBL5622327 | 0.84 | RAF1 (0.48) | TEKRAF1BRAF | |
| SCHEMBL5593016 | 0.83 | TEK (0.53) | TEKBRAFMEN1KMT2ANAMPT | |
| SCHEMBL5603184 | 0.83 | ABL1 (0.40) | TEKBRAFMEN1KMT2AABL1 | |
| SCHEMBL4551597 | 0.82 | MAPK14 (0.60) | RAF1BRAFNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007075896-A2 | HETEROCYCLIC CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075896-A2 | HETEROCYCLIC CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-07-05 | — | — | WO | disclosed |